Xiamen Spacegen.Co.,Ltd
生物技术研究
xiamen，Fujian 741 位关注者
Spacegen ? focus on Genomic and Molecular Oncology Provide NGS ，Real-Time PCR ，Digital PCR Gene Mutations Detection Kit.
关于我们
Xiamen SpacegenCo., Ltd., Specializing in the development, manufacture and marketing of diagnostic tests for targeted therapies in oncology. Spacegen’s patented diagnostic technology makes early targeted screening, drug selection and efficacy monitoring efficient and are cost-effective. Spacegen has 3500 ㎡GMP production areas,2000㎡ R&D/QC laboratories and1500 ㎡ office areas. Subsidiary Laboratory includes Xiamen SpaceSeq MedLab Co., Ltd and Suzhou SpaceSeq MedLab Co., Ltd which has medical institution practice license and is in accordance with the P2+ standard. Spacegen? has developed patent technologies including RingCap? (Ring-Link Capture Library technology) and PAP-ARMS (pyrophosphorolysis-activated polymerization amplification refractory mutation system) RingCap? advantages: (1) Ease of Use: Based on the independent patent technology RingCap?, Library preparation in 2 steps..; (2)Fast Results： The library preparation takes only 3.5 hours, 2 working days from sampling to reporting. (3) High Sensitivity and Comprehensive Coverage. (4)Multiple Instruments: Reagents are compatible with Illumina? NextSeq 500, MiniSeq, and MiSeq and Ion Torrent PGMS5,Proton sequencers. PAP-ARMS Technical advantages: (1). Accuracy and Reliability:Use sub-packed PCR tube to effectively avoid cross-contamination. (2)High Sensitivity and Comprehensive Coverage. (3)Great versatility: Validated on the most common qPCR machines with stable results.
- 网站
-
https://www.sspacegen.com
Xiamen Spacegen.Co.,Ltd的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- xiamen，Fujian
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Molecular Diagnostics、Cancer diagnostic、NGS、Real-time PCR、Company diagnostics 、drug selection、 efficacy monitoring efficient 、Library preparation 、Oncology Detection 、Targeted therapies、Biomarker Dtection 、Digital PCR 、Nucleic Acid Mass Spectrometry、Gene Mutations Detection 和Next Generation Sequencing
地点
-
主要
获取路线
NO.2041,XizhouRoad,Xike Town,Tong'an District,Xiamen
CN，Fujian，xiamen，361100
Xiamen Spacegen.Co.,Ltd员工
动态
-
World Tuberculosis Day #WorldTuberculosisDay
-
-
Recently,SpaceGen, in collaboration with multiple hospitals across the country, has launched the "Walk Together for Good, Support Women's Love" public welfare activity for the March 8th Women's Day. This initiative offers free genetic testing to women who have been diagnosed with gynecological tumors.
-
On March 10, 2025, the antibody-coupled drug (ADC) targeting human trophoblast surface antigen 2(TROP2), Sacituzumab Tirumotecan?(sac-TMT, trade name: Gatorade), was granted a second indication by National Medical Products Administration (NMPA). For the treatment of advanced locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC) adult patients with positive EGFR mutations following treatment with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and platinum-containing chemotherapy, the first TROP2 ADC drug approved worldwide for lung cancer indications.